The size of the Sepsis Diagnostics Market in the Asia Pacific is predicted to value USD 325.48 million by 2026 from USD 204.97 Million in 2021, growing at a CAGR of 9.69% from 2021 to 2026.
The development of technologically better diagnostic methods and an increase in the prevalence of sepsis are anticipated to be the key drivers promoting market expansion. Also, due to the increase in the incidences, demand for diagnostic solutions is expected to rise, and spreading awareness with the help of government initiatives is further expected to contribute to the market growth.
In addition, an increase in the number of pneumonia cases and market key players as they come up with innovations and better advancements boost the market growth. Moreover, the increase in financing for sepsis-related research activities, an increase in the number of sepsis procedures with rising prevalence of antibiotic-resistant bacterial strains, and fewer long-lasting problems are further likely to expand the market growth.
However, the shortage of skilled professionals in the healthcare industry has always been a significant challenge among the countries as it limits the growth of the APAC sepsis diagnostics market. In addition, sepsis diagnostics also cost a considerable amount, and it also restricts the development of the sector. Also, the absence of established standards for the treatment of sepsis in certain countries and a lack of knowledge about the consequences that sepsis can bring if not being addressed are the factors that can be barriers to market growth.
This research report on the APAC sepsis diagnostics market has been segmented and sub-segmented into the following categories:
By Pathogen:
By Product:
By Technology:
By Method:
By Usability:
By Country:
The Asia Pacific sepsis diagnostics market is expected to see attractive growth over the forecast period. The major players operating in the marketplace are adopting organic growth strategies, such as product development and launch, to grow the market significantly. For example, in August 2018, Sysmex Corporation launched a new HISCL presepsin assay kit. This kit is designed to measure the level of presepsin, a key test parameter for bacterial sepsis. Also, the high prevalence of sepsis in key Asia Pacific countries is foreseen to drive demand for diagnostic solutions. For example, according to the 2019 report published by the PLOS Journal, India has a very high incidence of clinical sepsis. Around 17,000 births out of 100,000 were affected.
The Asia-Pacific region dominated the overall market quantitatively. The growing number of neonatal cord blood sepsis cases in India, Pakistan, and China has created significant opportunities in the Asia-Pacific sepsis diagnostic market. According to a study by Mullany, Nepal found 16%, approximately 5,212 million deaths of umbilical cord infections in five countries, including India, Pakistan, China, and others.
KEY MARKET PLAYERS:
A few of the noteworthy players dominating the APAC sepsis diagnostics market profiled in the report are bioMérieux SA, T2 Biosystem Inc, Cepheid, Thermo Fisher Scientific Inc., Nanosphere Inc, Abbott Laboratories, Roche Diagnostics Limited, Becton, Dickinson and Company, Bruker Corporation, and Beckman Coulter, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Pathogen
5.1.1 Introduction
5.1.2 Bacterial Sepsis
5.1.2.1 Gram-Negative Bacterial Sepsis
5.1.2.2 Gram-Positive Bacterial Sepsis
5.1.3 Fungal Sepsis
5.1.4 Other Pathogen Infections
5.1.5 Y-o-Y Growth Analysis, By Pathogen
5.1.6 Market Attractiveness Analysis, By Pathogen
5.1.7 Market Share Analysis, By Pathogen
5.2 Product
5.2.1 Introduction
5.2.2 Instruments
5.2.3 Blood Culture Media
5.2.4 Assay Kits & Reagents
5.2.5 Software
5.2.6 Y-o-Y Growth Analysis, By Product
5.2.7 Market Attractiveness Analysis, By Product
5.2.8 Market Share Analysis, By Product
5.3 Technology
5.3.1 Introduction
5.3.2 Microbiology
5.3.3 Molecular Diagnostics
5.3.4 Immunoassays
5.3.5 Flow Cytometry
5.3.6 Other Technologies
5.3.7 Y-o-Y Growth Analysis, By Technology
5.3.8 Market Attractiveness Analysis, By Technology
5.3.9 Market Share Analysis, By Technology
5.4 Method
5.4.1 Introduction
5.4.2 Convential Diagnostics
5.4.3 Automated Diagnostics
5.4.4 Y-o-Y Growth Analysis, By Method
5.4.5 Market Attractiveness Analysis, By Method
5.4.6 Market Share Analysis, By Method
5.5 Usability
5.5.1 Introduction
5.5.2 Laboratory Testing
5.5.3 Point-of-Care Testing
5.5.4 Y-o-Y Growth Analysis, By Usability
5.5.5 Market Attractiveness Analysis, By Usability
5.5.6 Market Share Analysis, By Usability
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Pathogen
6.1.3.3 By Product
6.1.3.4 By Technology
6.1.3.5 By Method
6.1.3.6 By Usability
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Pathogen
6.1.4.3 By Product
6.1.4.4 By Technology
6.1.4.5 By Method
6.1.4.6 By Usability
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Pathogen
6.1.5.3 By Product
6.1.5.4 By Technology
6.1.5.5 By Method
6.1.5.6 By Usability
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 bioMérieux SA
8.1.1 Overview
8.1.2 Pathogen Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 T2 Biosystem Inc
8.3 Cepheid
8.4 Thermo Fisher Scientific Inc.
8.5 Nanosphere Inc
8.6 Abbott Laboratories
8.7 Roche Diagnostics Limited
8.8 Becton, Dickinson and Company
8.9 Bruker Corporation
8.10 Beckman Coulter, Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
